FDA set to evaluate use of ‘ecstasy’ for treating PTSD

Midomafetamine (MDMA)-assisted therapy may soon be approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). The agency is set to deliberate on its recommendation June 4, bringing in a panel of outside experts to weigh in. 

The application was submitted by Lykos Therapeutics, which is seeking the ability to investigate MDMA-assisted therapies and develop new drugs. MDMA currently has a Schedule 1 classification with the Drug Enforcement Administration (DEA), which designates a substance the agency believes to have no medicinal value. 

However, Lykos contends MDA—more commonly known as “ecstasy”—could be a powerful treatment tool, and it backs its claim with two late-stage studies. The company earned a New Drug Application approval from the FDA in February to study MDA in combination with psychotherapy and other psychiatric interventions. 

"This will be the first MDMA-assisted therapy and psychedelic-assisted therapy to be reviewed by the Psychopharmacologic Drugs Advisory Committee, a significant milestone in the field of psychedelic medicine, resulting from decades of clinical research and advocacy," Amy Emerson, CEO of Lykos Therapeutics said in a statement. "We look forward to the opportunity to discuss the comprehensive data package of investigational MDMA and how, if approved, it may be used as a prescription treatment in combination with psychological intervention in adults with PTSD."

The June 4 meeting will mark the first time in 25 years the FDA has examined a new potential treatment for PTSD. To date, no psychedelic-based therapy has been approved in the U.S.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

A string of executive orders from the White House created serious concerns among radiologists and other healthcare providers throughout the United States. The American College of Radiology issued a statement to help guide its members through the chaos. 

Bridgefield Capital, founded in 2015, has previously invested in such popular brands as Cirque Du Soleil, Del Monte and Quiksilver. This transaction is expected to be completed in the second half of 2025. 

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it.